Samsara BioCapital LLC Sells 22,526 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Samsara BioCapital LLC lowered its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 50.0% during the third quarter, HoldingsChannel reports. The fund owned 22,526 shares of the company’s stock after selling 22,526 shares during the quarter. Samsara BioCapital LLC’s holdings in Janux Therapeutics were worth $1,023,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of JANX. Summit Securities Group LLC bought a new stake in shares of Janux Therapeutics during the second quarter worth about $29,000. Amalgamated Bank boosted its position in Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after buying an additional 368 shares during the period. Plato Investment Management Ltd bought a new stake in Janux Therapeutics during the 2nd quarter worth approximately $42,000. Mirae Asset Global Investments Co. Ltd. increased its position in Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after acquiring an additional 339 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Janux Therapeutics during the second quarter valued at $151,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insiders Place Their Bets

In other news, CEO David Alan Campbell sold 15,000 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a total value of $1,005,000.00. Following the completion of the sale, the chief executive officer now owns 242,054 shares in the company, valued at $16,217,618. This represents a 5.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $46.24, for a total transaction of $44,297.92. Following the transaction, the insider now owns 6,887 shares in the company, valued at approximately $318,454.88. This trade represents a 12.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 460,610 shares of company stock valued at $21,583,666. Corporate insiders own 29.40% of the company’s stock.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock opened at $66.84 on Thursday. Janux Therapeutics, Inc. has a 52 week low of $7.79 and a 52 week high of $71.25. The stock has a 50 day moving average price of $49.83 and a two-hundred day moving average price of $45.81.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics’s revenue was down 82.6% compared to the same quarter last year. As a group, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

JANX has been the subject of several analyst reports. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research note on Thursday, November 7th. Stifel Nicolaus increased their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday. HC Wainwright boosted their price target on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $79.90.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.